Log In
BCIQ
Print this Print this
 

Saphris, Sycrest, asenapine (ME2136, SCH 900274)

  Manage Alerts
Collapse Summary General Information
Company Merck & Co. Inc.
DescriptionSerotonin (5-HT2) receptor and dopamine D2 receptor antagonist
Molecular Target Serotonin (5-HT2) receptor ; Dopamine D2 receptor
Mechanism of ActionDopamine receptor antagonist; Serotonin (5-HT) receptor antagonist
Therapeutic ModalitySmall molecule

 Product Details
Disease CategoryStandard IndicationIndication DetailsPartnersMilestonesLatest Stage of DevelopmentRegulatory Designation
 Archive Items are loading loading
Collapse Summary Deals Information
Total Number of DealsTotal Deal ValueTotal Upfront CashTotal Milestone Payments

2

0

$240.0M

0


 Deals Details
DateCompanies InvolvedDeal HeadlineTotal Deal ValueTotal Upfront CashTotal Milestone

12/09/2013

Undisclosed

$240.0M

Undisclosed

10/18/2010

Undisclosed

Undisclosed

0

Get a free BioCentury trial today